Telix, Grupo RPH ink production & distribution agreement in Brazil
Category: #health  By Mateen Dalal  Date: 2019-07-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

Telix, Grupo RPH ink production & distribution agreement in Brazil

The agreement gives Grupo RPH exclusive right to manufacture and distribute the TLX591-Cdx in the Latin American market

Clinical-stage biopharmaceutical firm Telix Pharmaceutical has reportedly signed a manufacturing and distribution agreement with Grupo RPH.

Grupo RPH will become the contract manufacturer as well as distributor for Telix in Brazil. According to an official statement, their initial focus as partners will be on TLX591-CDx (68Ga-PSMA-11) for prostate cancer imaging, but the contract agreement is built so as to allow Telix to include other products as well later on.

Rafael Madke, Grupo RPH Managing Director stated that Telix’s rapid expansion over the past year has been remarkable, and with Grupo RPH holding the upper hand in the Brazilian market owing to its proficiency to fabricate and distribute radiopharmaceuticals, the company will be able to support Telix’s commercial goals cost-effectively.

Telix Vice President for Corporate Development, Ludovic Wouters was quoted saying that the alliance offers their gallium-68 based nuclear medicinal products a massive and rapidly growing market. He further added they were looking forward to working with Grupo RPH to introduce their prostate cancer imaging technology into the Latin American market.

For the uninitiated, Telix Pharmaceuticals Limited is a global clinical-stage biopharmaceutical corporation aimed at the development of therapeutic and diagnostic radiopharmaceutical products based on molecularly targeted radiation (MTR). The Melbourne-headquartered company has international businesses in Indianapolis (US), Brussels (UK), and Kyoto (Japan).

Supposedly, the company is aiming to develop a portfolio of clinical-stage oncology offerings which can tackle numerous unmet needs of patients with prostate, renal and brain cancer.

Grupo RPH commercially offers 8 different Cold Kits for Ga68 and Tc99m manufacturing in the Brazilian market. The firm also owns the GMP manufacturing facility based in Brazil for radiopharmaceutical products and exports its products throughout the country for serving more than 400 customers every day. The company is also known to have pioneered Brazil’s centralized radio-pharmacy model.

 

Source credit: https://www.globenewswire.com/news-release/2019/07/03/1877635/0/en/Telix-Pharmaceuticals-and-Grupo-RPH-Sign-LATAM-Manufacturing-and-Distribution-Agreement.html?print=1

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Novo Nordisk and Medtronic team up to offer digital diabetes solutions
Novo Nordisk and Medtronic team up to offer digital diabetes solutions
By Mateen Dalal

With growing population of diabetic patients, diabetes management is becoming a daunting activity. Sugar level management and insulin injections tracking is a difficult work. Thus, leading pharmaceutical companies are collaborating with medical devic...

Akesis unveils its advanced Galaxy™ RTi and Gemini360 at ASTRO 2019
Akesis unveils its advanced Galaxy™ RTi and Gemini360 at ASTRO 2019
By Mateen Dalal

The healthcare company will showcase its drugs in the ASTRO annual meeting 2019 that could help offer improved efficiency and confidence in treatment delivery. Akesis, Inc., a hospital and healthcare company based in the U.S. that offers innovative...

Adverum reveals positive results from Phase 1 trial of ADVM-022
Adverum reveals positive results from Phase 1 trial of ADVM-022
By Mateen Dalal

The drug was well tolerated and was safe, and has shown the capacity to improve the treatment paradigm for patients with wet AMD. Adverum Biotechnologies, Inc., a company that develops medical therapies for ocular and rare diseases, recently announc...